Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:08:17.277Z.
Calculation as of: 2026-10-06T18:08:17.277Z.
Quote observation: 2026-10-06T18:05:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: eea6c7d5cd6e3fe508f4e89a8ac0afa25f3437e05bd10ab9ad2dfceb562d4ef8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$97.28M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$92.33M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$102.64M
EV/EBIT Ratio
57.50x
TTM Avg
89.36x
3Y Avg
94.92x
5Y Avg
1303.85x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korro Bio, Inc. (KRRO) | $96.65M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.28M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $99.01M | N/A | N/A | N/A | N/A |
| PolyPid Ltd. (PYPD)vs › | $99.23M | 80.96x | 96.06x | 96.06x | 12.74x |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $92.33M | N/A | N/A | N/A | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $91.46M | N/A | N/A | N/A | N/A |
| Rallybio Corporation (RLYB)vs › | $90.32M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $102.64M | 57.50x | 89.36x | 94.92x | 1303.85x |
| Equillium, Inc. (EQ)vs › | $90.41M | N/A | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $103.06M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute